Dupixent cleared for chronic rhinosinusitis in EU; FDA grants RMAT status to CARsgen's CAR-T
→ Regeneron and Sanofi‘s Dupixent — a king in the eczema therapy sector — has cinched its third type 2 inflammatory disease approval in the EU. On top of severe asthma and moderate-to-severe atopic dermatitis, the drug can now be given to adults who have severe chronic rhinosinusitis with nasal polyposis (CRSwNP). It will be used as an add-on therapy with intranasal corticosteroids to treat patients for whom therapy with systemic corticosteroids and/or surgery do not provide adequate disease control.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
